Domengé Orianne, Ragot Hélène, Deloux Robin, Crépet Agnès, Revet Gaëlle, Boitard Solène Emmanuelle, Simon Alexandre, Mougenot Nathalie, David Laurent, Delair Thierry, Montembault Alexandra, Agbulut Onnik
Université de Lyon, Université Claude Bernard Lyon 1, CNRS, Ingénierie des Matériaux Polymères, IMP UMR 5223, 15 bd A. Latarjet, F-69622, Villeurbanne, France.
Sorbonne Université, Institut de Biologie Paris-Seine (IBPS), CNRS UMR 8256, Inserm ERL U1164, Biological Adaptation and Ageing, 7 quai St-Bernard (case 256), F-75005, Paris, France.
Acta Biomater. 2021 Jan 1;119:125-139. doi: 10.1016/j.actbio.2020.10.045. Epub 2020 Nov 6.
This work explores the epicardial implantation of acellular chitosan hydrogels in two murine models of cardiomyopathy, focusing on their potential to restore the functional capacity of the heart. Different chitosan hydrogels were generated using polymers of four degrees of acetylation, ranging from 2.5% to 38%, because the degree of acetylation affects their degradation and biological activity. The hydrogels were adjusted to a 3% final polymer concentration. After complete macromolecular characterization of the chitosans and study of the mechanical properties of the resulting hydrogels, they were sutured onto the surface of the myocardium, first in rat after four-weeks of coronary ligation (n=58) then in mice with cardiomyopathy induced by a cardiac-specific invalidation of serum response factor (n=20). The implantation of the hydrogels was associated with a reversion of cardiac function loss with maximal effects for the acetylation degree of 24%. The extent of fibrosis, the cardiomyocyte length-to-width ratio, as well as the genes involved in fibrosis and stress were repressed after implantation. Our study demonstrated the beneficial effects of chitosan hydrogels, particularly with polymers of high degrees of acetylation, on cardiac remodeling in two cardiomyopathy models. Our findings indicate they have great potential as a reliable therapeutic approach to heart failure.
本研究在两种心肌病小鼠模型中探索了脱细胞壳聚糖水凝胶的心外膜植入,重点关注其恢复心脏功能能力的潜力。使用四种乙酰化程度从2.5%到38%的聚合物制备了不同的壳聚糖水凝胶,因为乙酰化程度会影响它们的降解和生物活性。将水凝胶调整至最终聚合物浓度为3%。在对壳聚糖进行了完整的大分子表征并研究了所得水凝胶的机械性能后,将它们缝合到心肌表面,首先是在冠状动脉结扎四周后的大鼠中(n = 58),然后是在因血清反应因子心脏特异性无效诱导的心肌病小鼠中(n = 20)。水凝胶的植入与心脏功能丧失的逆转相关,乙酰化程度为24%时效果最佳。植入后,纤维化程度、心肌细胞长宽比以及参与纤维化和应激的基因均受到抑制。我们的研究证明了壳聚糖水凝胶,特别是高度乙酰化聚合物,在两种心肌病模型中对心脏重塑的有益作用。我们的研究结果表明,它们作为心力衰竭的可靠治疗方法具有巨大潜力。